210 related articles for article (PubMed ID: 33742748)
21. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More
Griese M; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Taylor-Cousar JL; Withers NJ; Moskowitz SM; Daines CL
Am J Respir Crit Care Med; 2021 Feb; 203(3):381-385. PubMed ID: 32969708
[No Abstract] [Full Text] [Related]
22. Persistence and evolution of
Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
[TBL] [Abstract][Full Text] [Related]
23. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
24. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
Young D; Bartlett LE; Guimbellot J; Milinic T; Burdis N; Gill ER; Lease ED; Goss CH; Kapnadak SG; Ramos KJ
J Cyst Fibros; 2024 May; 23(3):545-548. PubMed ID: 37798159
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.
Loske J; Völler M; Lukassen S; Stahl M; Thürmann L; Seegebarth A; Röhmel J; Wisniewski S; Messingschlager M; Lorenz S; Klages S; Eils R; Lehmann I; Mall MA; Graeber SY; Trump S
Am J Respir Crit Care Med; 2024 Jun; 209(11):1338-1350. PubMed ID: 38259174
[No Abstract] [Full Text] [Related]
26. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators.
George A; Smith B; Sawicki GS; Goetz DM
Pediatr Pulmonol; 2020 Nov; 55(11):2983-2989. PubMed ID: 32589808
[TBL] [Abstract][Full Text] [Related]
27. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease.
B B; A R; G R; A N; D G; S G; P F; M SG; L C; B G
J Cyst Fibros; 2021 Sep; 20(5):768-771. PubMed ID: 34162524
[No Abstract] [Full Text] [Related]
28. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
[TBL] [Abstract][Full Text] [Related]
29. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
30. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on
Huang Y; Paul G; Lee J; Yarlagadda S; McCoy K; Naren AP
Am J Respir Crit Care Med; 2021 Nov; 204(10):1231-1235. PubMed ID: 34379998
[No Abstract] [Full Text] [Related]
31. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
32. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
[No Abstract] [Full Text] [Related]
33. Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
Stewart KL; Szczesniak R; Liou TG
Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242
[TBL] [Abstract][Full Text] [Related]
34. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
35. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
37. Year in review 2023 - Back to the future.
Cristiani L; Fernandes FF
J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442
[TBL] [Abstract][Full Text] [Related]
38. Tezacaftor for the treatment of cystic fibrosis.
Sala MA; Jain M
Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
[TBL] [Abstract][Full Text] [Related]
39. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
40. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
